At Morphosys, a change in the position of CFO is due at the end of the year: The company’s long-standing CFO, Jens Holstein, will be leaving the company at the end of 2020. Holstein will “exercise his function until the end of the year in order to ensure a smooth transition of business,” announced the TecDAX-listed biotech company on Thursday night. Holstein wants to tackle new professional challenges, they say.
So far there is no succession plan. The search for a successor to the Chief Financial Officer has begun, according to Morphosys.
â € œSince joining in 2011, Jens has made a significant contribution to making the company the success story it is today. He leaves MorphoSys operationally and financially in a position that will enable us to continue delivering therapies to patients with high medical needs in the years to come, “said Marc Cluzel, Chairman of the Company’s Board of Directors.
More about biotech stocks on 4investors: click here
At a glance – chart and news: MorphoSys